Hormonal
Blockade of central GLP-1 receptors using the antagonist Exendin 9–39 (Ex9) improves glucose tolerance and fasting glycemia in diabetic mice fed a high-fat diet.
In a diabetic state induced by high-fat diet, blocking central GLP-1 receptors with Ex9 for one month normalized fasting blood sugar and improved glucose tolerance. This suggests that the central GLP-1 pathway may contribute to metabolic dysfunction in obesity/diabetes, and its blockade can have therapeutic benefits in this specific context.
In diabetic mice fed a high-fat diet, a 1-month chronic i.p. Ex9 treatment improved glucose tolerance and fasting glycemia.
Why this rating
Clear improvement in clinical markers (glucose tolerance, fasting glycemia) in a relevant animal model.
Source
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
Claude Knauf · Journal of Clinical Investigation · 2005
DOI 10.1172/jci25764
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →